Abstract
Hepatocellular carcinoma (HCC) has five characteristics that are strikingly different from those of other malignant tumors of the digestive system: (1) a strong causal relationship with hepatitis viruses (especially type B and type C), (2) a major impact of the status of hepatic functional reserve and liver damage on the choice of treatment and the prognosis, (3) a high recurrence rate, with many of the recurrences developing within the liver, and the existence of two major routes of recurrence, i.e., multicentric carcinogenesis and intrahepatic metastasis, (4) the possibility of performing effective treatment, if confined to the liver and liver functional reserve permits, and (5) the existence of a clear outcome determinant as vascular invasion. Because of these characteristics, choosing the method of treatment for HCC is not easy, although several useful methods are available to treat HCC.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Makuuchi M, Kokudo N (2006) Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 12:828–829
Makuuchi M, Kokudo N, Arii S et al (2008) Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 38:37–51
Liver Cancer Study Group of Japan (1997) Classification of primary liver cancer. Kanehara & Co., Ltd., Tokyo p. 21
Makuuchi M, Kosuge T, Takayama T et al (1993) Surgery for small liver cancers. Semin Surg Oncol 9:298–304
Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236
Ishizawa T, Hasegawa K, Aoki T et al (2008) Multiple tumors and concomitant portal hypertension are not operative contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–1916
Vauthey JN, Lauwers GY, Esnaola NF et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536
Arii S, Yamaoka Y, Futagawa S et al (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 32:1224–1229
Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739
Minagawa M, Makuuchi M, Takayama T et al (2001) Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 233:379–384
Eddy DM (1990) Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 263:3077, 3081, 3084
Kokudo N, Sasaki Y, Nakayama T et al (2007) Dissemination of evidence-based clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons, and primary care physicians. Gut 56:1020–1021
Lencioni RA, Allgaier HP, Cioni D et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–240
Shiina S, Teratani T, Obi S et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129:122–130
Huang GT, Lee PH, Tsang YM et al (2005) Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 242:36–42
Chen MS, Li JQ, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for hepatocellular carcinoma. Ann Surg 243:321–328
Hasegawa K, Kokudo N, Makuuchi M (2008) Surgery or ablation for hepatocellular carcinoma? Ann Surg 247:557–558
Hasegawa K, Makuuchi M, Takayama T, et al. for the Liver Cancer Study Group of Japan (2008) Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 49:589–594
Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group (2007) Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 13(11 Suppl 2): S48–S54
Llovet JM, Ricci S, Mazzaferro V, et al. for SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hasegawa, K., Kokudo, N. (2011). Evidence-Based Guidelines for Treatment of Hepatocellular Carcinoma in Japan. In: McMasters, K. (eds) Hepatocellular Carcinoma:. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-522-4_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-522-4_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-60327-521-7
Online ISBN: 978-1-60327-522-4
eBook Packages: MedicineMedicine (R0)